MSKCC

Santa Ana Bio Launches With $168 Million to Advance Precision Medicines for Inflammatory Diseases

Retrieved on: 
Donnerstag, Juni 13, 2024
Biotechnology, General Health, Pharmaceutical, Health, King's College London, Patient, Collateral damage, GV, Rockefeller University, International Chinese Language Program, Infection, CSO, Safety, Glucocorticoid, Dean, Versant, Rheumatoid arthritis, Howard Hughes Medical Institute, Cytokine, Autoimmunity, B cell, MSKCC, Cornell University, Toxicity, University, Drug development, Research, Faculty, Immunology, Pathology, Autoimmune disease, Associate, MedImmune, RTW, Doctor of Philosophy, Kite Pharma, Antibody, ADC, Neutropenia, Senior, Inflammation, PD-1, Spacecraft, King's Health Partners, Yale School of Medicine, Stanford Cancer Institute, Stanford University, Cell, Vaccine

Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today emerged from stealth with $168 million in combined Series A and B funding.

Key Points: 
  • Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today emerged from stealth with $168 million in combined Series A and B funding.
  • Santa Ana employs proteomic, transcriptomic and genomic approaches to precisely characterize disease-specific subpopulations and identify targets only on disease-causing cell types leaving healthy cells unaffected.
  • “Precision medicines offer the ability to target defined cell types and pathways to disrupt the pathogenic biology driving disease,” said Peter Emtage, Ph.D., CEO and board member of Santa Ana and a venture partner at Versant.
  • Since the company was launched in 2022, Santa Ana has advanced three programs that are poised to enter the clinic starting next year.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

Retrieved on: 
Montag, Mai 6, 2024
Charcot–Marie–Tooth disease, FDA, Venetoclax, OHSU, Innovation, National Cancer Institute, BPD, Development, IND, CNS, NET, Schizophrenia, EVOLUTION, JHU, Azacitidine, NCI, FCCC, Deficit spending, IP, Paclitaxel, IIS, Food, European Patent Convention, CMT, Borderline personality disorder, Communication, Conference, AML, Aggression, Convertible bond, FMS, ALS, Phase, Kabuki syndrome, HOPE, Safety, SCLC, DSM-IV codes, EMA, Clinical trial, Medicine, EPO, Investigational New Drug, Duration, Platinum, Bangladesh Technical Education Board, Phase II, MRD, ICIS, MSKCC, Disease, Measure (mathematics), CRADA, Dor, Patent, HDAC6, Data analysis, Genomics, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.
  • Research and development (R&D) expenses were $2.6 million for the quarter ended March 31, 2024, compared to $4.4 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $0.9 million for the quarter ended March 31, 2024, compared to $1.2 million for the quarter ended March 31, 2023.
  • Net losses were $1.1 for the quarter ended March 31, 2024, respectively, compared to $1.4 million for the quarter ended March 31, 2023.

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

Retrieved on: 
Mittwoch, Mai 8, 2024
Radiology, Pharmaceutical, Research, Oncology, Software, Medical Devices, Hospitals, Genetics, Data Management, Stem Cells, Science, Practice Management, Technology, Clinical Trials, Medical Supplies, FDA, Biotechnology, Surgery, Health, CO, Cancer, Depreciation, Webcast, DdPCR, Forecasting, Growth, MSKCC, Net operating loss, Patient, COVID-19, Acquisition, Adjustment, AACR, Bank statement, EGFR, GAAP, AstraZeneca

In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.

Key Points: 
  • In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.
  • Our team is off to a strong start, helping to impact more patients every quarter in the large and underserved lung nodule diagnostic testing market.
  • Record quarterly gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023.
  • The Company reaffirms its 2024 financial outlook and expects to generate between $65 million and $68 million in total revenue in 2024.

Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of American Society of Hematology (ASH) Peter Steelman Scholar Award

Retrieved on: 
Montag, Mai 6, 2024
University, Bone marrow, Summit, Cancer, Hospital, Blood, Oncology, Partnership, Research, AML, MSKCC, Senior, ASH, Patient, Society, Harvard Medical School, Boston Children's Hospital, Division, Dana–Farber Cancer Institute

NEW YORK, May 6, 2024 /PRNewswire/ -- Deerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second annual Acute Myeloid Leukemia (AML) Summit. The AML Summit convenes industry experts, leaders, and partners across healthcare to further advance research on this cancer of the bone marrow and blood.

Key Points: 
  • NEW YORK, May 6, 2024 /PRNewswire/ -- Deerfield Management and the Deerfield Foundation announced today they will honor the 2023-2024 recipients of the American Society of Hematology (ASH) Peter Steelman Scholar Award at the second annual Acute Myeloid Leukemia (AML) Summit.
  • The AML Summit convenes industry experts, leaders, and partners across healthcare to further advance research on this cancer of the bone marrow and blood.
  • Her research has identified novel molecular dependencies in this AML subtype, contributing to the development of targeted epigenetic drugs that are in early-phase clinical trials.
  • Dr. Haubner is a physician-scientist specializing in chimeric antigen receptor (CAR) therapies for safe and efficient targeting of AML.

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Retrieved on: 
Mittwoch, April 17, 2024
Combination, Safety, Ophthalmology, Oncology, Dietary supplement, Polysaccharide, Immunotherapy, Partnership, Research, IND, CNS, Non-small-cell lung cancer, MSKCC, Lung cancer, Grifola frondosa, Therapy, Patient, Combination therapy, Edible, Myelodysplastic syndrome, Health, Triple-negative breast cancer, Clinical trial, MDS, Ergosterol, TNBC, US FDA, Investigational New Drug, Virginity, Pharmaceutical industry

The Investigational New Drug (IND) application for ABV-1519 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy.

Key Points: 
  • The Investigational New Drug (IND) application for ABV-1519 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy.
  • We believe that this collaboration leverages the respective strengths of both companies to accelerate the availability of this vital treatment to patients worldwide.
  • This licensing agreement exemplifies ABVC and OncoX's shared dedication to advancing medical science and improving patient care.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts: visit https://abvcpharma.com/?page_id=17707

Fiduciary Trust International Welcomes Edward J. Mooney as Managing Director and Financial Planning Director

Retrieved on: 
Mittwoch, Mai 1, 2024
Personal Finance, Finance, Consulting, Professional Services, Asset Management, Franklin Templeton Investments, BNY Mellon, MSKCC, JD, NewYork-Presbyterian Hospital, Fordham University, Investment, Fiduciary Trust Company International, New York Law School, Hospital, Fortune 500, Management

Fiduciary Trust International, a global wealth manager and wholly-owned subsidiary of Franklin Templeton, announces that Edward J. Mooney is joining the firm as managing director and financial planning director.

Key Points: 
  • Fiduciary Trust International, a global wealth manager and wholly-owned subsidiary of Franklin Templeton, announces that Edward J. Mooney is joining the firm as managing director and financial planning director.
  • He will oversee the continuous innovation of the firm’s financial planning offering.
  • “Ed’s extensive industry experience perfectly complements our mission and commitment to delivering exceptional, best-in-class financial planning solutions to our clients,” said Leslie Gillin Bohner, chief fiduciary officer of Fiduciary Trust International.
  • “I’m honored to join the team at Fiduciary Trust International and contribute to the legacy of a firm deeply rooted in familial values, and committed to safeguarding and enhancing our clients’ wealth through generations,” said Mr. Mooney.

Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer

Retrieved on: 
Mittwoch, April 24, 2024
Oncology, Medical Devices, Health, Hospitals, Clinical Trials, Biotechnology, Cancer, HNSCC, MRD, Recurrence, Doctor of Philosophy, Research, MSKCC, DNA, Patient, HPV, Head, Neoplasm, TTMV

Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer.

Key Points: 
  • Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer.
  • The study will be led by Memorial Sloan Kettering Cancer Center (MSKCC), a top cancer treatment and research institution.
  • “This study will propose a novel intervention for patients with MRD+ HPV-driven head and neck cancer and will assess the ability of NavDx to identify MRD in these patients,” said Alan L. Ho, MD, PhD, Head and Neck Oncologist and Cellular Therapist, Memorial Sloan Kettering, and the primary principal investigator for the study.
  • We are grateful to the research team at Memorial Sloan Kettering Cancer Center for their collaboration and we look forward to presenting the results of this study when they are complete.”

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

Retrieved on: 
Montag, April 8, 2024
JHU, NCI, Development, Carcinoma, CRADA, National Cancer Institute, MSKCC, IND, Investigational New Drug, Genomics, Immune system, Bangladesh Technical Education Board, FDA, SCLC, Food, Pharmaceutical industry

This will be the first clinical trial testing the combination of iadademstat with immune checkpoint inhibitors.

Key Points: 
  • This will be the first clinical trial testing the combination of iadademstat with immune checkpoint inhibitors.
  • The trial ( NCT06287775 ) is entitled “A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer”.
  • “We are very pleased that NCI has received the regulatory approval from the FDA to initiate this first-in-human Phase I/II combination trial with iadademstat plus immune check point inhibitors” stated Dr. Carlos Buesa, Chief Executive Officer of Oryzon.
  • “The molecular mechanisms underlying the ability of iadademstat to render small cell lung cancer cells visible to the immune system while simultaneously enhancing immune activity to aggressively target these malignant cells have been clearly elucidated.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Montag, Februar 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)

Retrieved on: 
Dienstag, Dezember 5, 2023
MSD, Metastasis, Principal, Merck & Co., Clinical trial, RCC, MSKCC, Patient, Safety, Therapy, GCN2, Renal cell carcinoma, Pharmaceutical industry

The Phase 1b study will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with WELIREG in participants with ccRCC.

Key Points: 
  • The Phase 1b study will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with WELIREG in participants with ccRCC.
  • With a focus on determining the recommended Phase 2 dose (RP2D), the study includes a dose-escalation phase followed by a dose-expansion phase and an independent HC-7366 monotherapy cohort.
  • The study is planned to open in Q1 2024 and will enroll up to 80 participants at clinical sites across the US.
  • “We are excited to collaborate with Merck to evaluate HC-7366 in combination with belzutifan,” said Jonathan Lanfear, President & CEO of HiberCell.